Original ArticlesPRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
Key Words
Cited by (0)
Disclosure: Borys Hrinczenko, J. Thaddeus Beck, Manuel R. Modiano, Robert W. Weaver, David R. Spigel, and Helen J. Ross have no conflict of interest to declare. Ralph G. Zinner received funding for research from Eli Lilly and Company. Petros G. Nikolinakos participated in the advisory boards meetings and received honoraria from Eli Lilly and Company. David M. Waterhouse was on the speaker's bureau for Eli Lilly and Company and received honoraria in the past. Ramaswamy Govindan is a consultant for Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Merck, Bayer, Covidien, Bristol-Myers Squibb, Genentech, and Mallinckrodt. Coleman K. Obasaju, Jingyi Liu, Andrew G. Koustenis, Katherine B. Winfree, Symantha A. Melemed, Susan C. Guba, Waldo I. Ortuzar, Durisala Desaiah, and Joseph A. Treat are employees of Eli Lilly and Company and may hold company stock.
Data from this study were presented at the 2013 annual meeting of American Society for Clinical Oncology, Chicago, IL, on June 3, 2013 (Abstract# LBA 8003) and at the World Conference on Lung Cancer, Sydney, Australia, October 28, 2013 (Abstract# P1.10–033).
ClinicalTrials.gov Identifier: NCT00948675.